Facts and controversies of aspirin and clopidogrel therapy

Area of Science:

• Cardiology
• Pharmacology
• Vascular Medicine

Background:

• Platelets play a central role in ischemic events and atherothrombosis.
• Aspirin and clopidogrel are cornerstone antiplatelet agents recommended in treatment guidelines.
• Despite established efficacy, controversies exist regarding their optimal clinical application.

Purpose of the Study:

• To review the current evidence and ongoing debates concerning aspirin and clopidogrel therapy.
• To address specific controversies including dosing, duration, combination therapy, and response variability.
• To provide clarity on the established benefits and unresolved issues in antiplatelet therapy.

Main Methods:

• Literature review of evidence-based treatment guidelines.
• Analysis of studies addressing dosing, duration, and combination therapy.
• Discussion of research on antiplatelet therapy response variability.

Main Results:

• Aspirin and clopidogrel demonstrate robust safety and efficacy profiles for atherothrombosis prevention.
• Significant debate persists regarding optimal dosing, treatment duration, and combination therapy strategies.
• Variability in patient response to antiplatelet therapy is a key area of ongoing research and clinical concern.

Conclusions:

• Antiplatelet therapy with aspirin and/or clopidogrel is an essential tool for managing atherothrombotic risk.
• Despite existing controversies, these agents remain proven and effective in specific clinical settings.
• Further research is needed to optimize antiplatelet therapy and address individual patient response variability.